水虫薬の世界市場-2023年～2030年

概要

世界の水虫薬市場は、2022年に12億米ドルに達し、2023～2030年の予測期間中にCAGR 7.8％で成長し、2030年には21億米ドルに達すると予測されています。スポーツや身体活動への参加の増加など、活動的なライフスタイルへのシフトなどの動向は、真菌が繁殖しやすい公共のシャワーにさらされるリスクを開発し、世界の水虫薬市場を独占すると予想されます。

世界の水虫薬市場は近年大きく成長しており、今後も上昇傾向が続くと予測されます。この市場は、自然でオーガニックな治療法に対する消費者の嗜好の高まりがハーブ系抗真菌製品の開発につながるなど、いくつかの重要な動向の影響を受けて変革期を迎えています。

さらに、真菌感染症や糖尿病などの感染症有病率の上昇、足の健康と衛生に対する意識の高まり、さらにOTC製品の入手可能性が水虫薬市場規模を押し上げています。水虫に関する研究活動が活発化していることや、質の高い医療専門家へのアクセスにより医療インフラが整備されていることも、北米地域の需要促進要因のひとつです。市場には、Novartis AG、Bayer AG、Vibcare Pharma Pvt. Ltd.などの競合企業が積極的に参入しています。

ダイナミクス

糖尿病患者の増加が水虫薬市場の成長を牽引

世界中で糖尿病の有病率が増加していることが、世界の水虫薬市場を大きく牽引すると予想されます。糖尿病は、体内の血糖値を上昇させる慢性の代謝性疾患であり、免疫システムの弱体化、循環障害、神経障害の原因となり、感染症のリスクを高め、迅速な治療が必要となります。

例えば、世界保健機関（WHO）の2023年報告書によると、世界中で約4億2,200万人が糖尿病に罹患しており、その大半は中低所得国に見られ、150万人が死亡しています。水虫になると、皮膚の乾燥、ひび割れ、感覚の鈍化が起こり、糖尿病を発症しやすくなり、再発もしやすくなります。したがって、糖尿病の有病率は、水虫薬市場内の糖尿病特有の課題に苦しんでいる人々のための効果的な治療薬への需要を推進するように、予測期間にわたって駆動することが期待されます。

肥満の有病率の増加が水虫薬市場の成長を促進する

世界の肥満人口の増加は、水虫薬市場を押し上げると予想されます。肥満は近年大きな問題となっており、足に深刻な影響を及ぼす可能性があります。例えば、世界保健機関（WHO）の2022年報告書によると、世界で約10億人が肥満であり、成人6億5,000万人、青年3億4,000万人、小児3,900万人を占めています。

足首の捻挫、足の疲れ、水ぶくれ、タコ、水虫などは、肥満の患者によく見られる足の病気です。太りすぎの人は、健康的な体重を維持するために不可欠な運動が困難になることもあります。さらに、肥満によって皮膚にしわが寄ったり、湿気が増えたりして、真菌が繁殖しやすい環境になっていることも多いです。従って、肥満人口の増加に伴い、起こりうる症状を管理・緩和するための効果的な薬剤が必要とされ、それが当面の市場を牽引することになります。

高齢者人口の増加が水虫薬市場の成長を牽引する

高齢者人口の増加は、高齢化によって足の健康が損なわれ、足に関連する問題につながる他の慢性疾患の合併症も併発しやすくなるなどの要因から、水虫薬市場を牽引すると予想されます。例えば、世界保健機関（WHO）の2022年報告によると、2030年までに世界の6人に1人が60歳以上になる見通しです。

さらに、60歳以上の高齢者は2020年の10億人から14億人に増加します。この疾患は女性に比べ男性に多く見られます。そのため、水虫のような真菌症に伴う不快感やリスク、個々の脆弱性に対処するための効率的な薬剤治療の必要性が高まっています。

水虫薬に関連する副作用が市場の成長を妨げる

水虫薬市場は、薬による副作用などの要因によって阻害されると予想されます。水虫薬の最も一般的な副作用は、灼熱感、刺痛、腫脹、刺激感、発赤、ニキビのようなしこり、痛み、治療部位の剥離などです。例えば、抗真菌薬であるケトコナゾールは、真菌を死滅させる作用があり、主に水虫の治療に使用されますが、水ぶくれ、痂皮（かさぶた）、皮膚の炎症や発赤などの副作用があります。

さらに、水虫の治療に使われる副腎皮質ステロイドは、このような数センチ幅の「両刃」模様のような、白癬の発疹に見られる異常な模様に大きな副作用をもたらすことがあります。このような副腎皮質ステロイド・クリームを長期間併用すると、白癬の発赤やほてりがひどくなることがあります。したがって、上記の要因によって、市場は予測期間中に大きな抑制要因に直面すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 糖尿病患者の増加
    • 肥満の有病率の上昇
    • 老年人口の増加
  • 抑制要因
    • 水虫薬に関連する副作用
  • 機会
    • 個別化医療への需要の高まり
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 タイプ別

• つま先型感染症
• モカシン型感染症
• 小水疱型感染症
• 潰瘍型感染症

第8章 製品タイプ別

• 局所用クリーム・軟膏
• スプレー
• ローション
• 経口薬
• その他

第9章 薬剤クラス別

• 抗真菌薬
• コルチコステロイド
• 抗生物質
• その他

第10章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• Novartis AG
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Vibcare Pharma Pvt. Ltd.
• Bayer AG
• Taro Pharmaceutical Industries Ltd
• GLENMARK PHARMACEUTICALS LTD.
• Abigail Healthcare Pharmaceutical
• Sebela Pharmaceuticals
• ANI Pharmaceuticals, Inc.
• Perrigo Company plc
• Xiromed

第14章 付録

Overview

Global Athlete's Foot Drugs Market reached US$ 1.2 billion in 2022 and is expected to reach US$ 2.1 billion by 2030 growing with a CAGR of 7.8% during the forecast period 2023-2030. The trend such as the shift towards active lifestyle such as growing participation in sport and physical activities develops the risk of exposure to public showers where fungus can trive, is expected to dominate the global athlete's foot drugs market.

The global athlete's foot drugs market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as the growing consumer preference towards natural and organic treatment options that leads to development of herbal antifungal products.

Furthermore, the rising prevalence of infectious disease such as fungal infections and diabetes, growing awareness health and hygiene of foot, moreover availability of OTC products are driving up the athlete's foot drugs market size. The growing research activities about the disease and presence of establish heathcare infrastructure due to access to quality medical professional are some of the factors in demand from North American regions. With significant competitors like Novartis AG, Bayer AG, Vibcare Pharma Pvt. Ltd., and others actively operating in the market.

Dynamics

The Increasing Prevalence of Diabetic People to Drive the Growth of the Athlete's Foot Drugs Market

The increasing prevalence of diabetes around the globe is expected to significantly drive the global athlete's foot drugs market. Diabetes is a chronic, metabolic disease that elevates the levels of blood glucose level in body, that leads to weakens the immune system, impairs circulation, and causes neuropathy, elevating the risk of infections and necessitating prompt treatment.

For instance, according to World Health Organization 2023 report, approximately 422 million people around the world are suffering from diabetes and the majority of cases are seen in low-and middle-income countries, that has led to 1.5 million deaths. As during athlete's foot dryness, cracking, and reduced sensation of skin occurs that leds to more vulnerability of disease having diabtes and can be recurrent too. Thus, as the prevalence of diabetes propel the demand for effective treatment for the people suffering diabetic-specific challenges within the athlete's foot drugs market is expected to drive over the forecast period.

The Rising Prevalence of Obesity will Drive the Athlete's Foot Drugs Market Growth

The growing prevalence of obese people across the globe is expected to boost the market of athlete's foot drugs. Obesity has become a major issue in recent years, and it can have severe consequences on feet. For instance, according to World Health Organization 2022 report, approximately 1 billion people globally are obesed that accounts 650 million adults, 340 million adolescents and 39 million children.

Sprained ankles, general foot fatigue, blisters, calluses, and athlete's foot are some of the most common foot disorders in obese patients. Overweight people may find it difficult to exercise, which is essential for keeping a healthy weight. Moreover, obesity frequently causes skin wrinkles and increased moisture in these regions, creating an environment favorable to fungal growth. Thus, as the obesed people population increases, there is major need of effective drugs to manage and alleviate the symtoms that are likely to occur and thereby driving the market over the foreseeable future.

The Growing Geriatric Population will Drive the Athlete's Foot Drugs Market Growth

The increasing elderly population is expected to drive the athlete's foot market owing to the factors such as the people age, they are more susceptible to have poor foot health, along with other chronic disease complications that lead to foot related problems. For instance, according to World Health Organization 2022 report, 1 in 6 people in the world will age above 60 years by 2030.

Furthermore, the people aging above 60 will increase from 1 billion in 2020 to 1.4 billion. This disorder is more prevalent in males compared to female population. Thus, there is increase the need for efficient drug treatments to address their individual vulnerabilities and the discomfort and risks associated with fungal diseases such as athlete's foot.

The Side Effects Associated with the Athlete's Foot Drugs Will Hamper the Growth of the Market

The athlete's foot drugs market is expected to be hamper owing to the factors such as side effects from the drugs. The most prevalent adverse reactions of athlete's foot medications are burning, stinging, swelling, irritation, redness, pimple-like lumps, soreness, or flaking of the treated area. For instance, Ketoconazole an antifungal drug that works by killing fungi that and is mostly given to treat athlete foot disease has some side effects such as blistering, crusting, irritated or red skin.

Moreover, corticosteroid used to treat athlete foot disease can have major side effects unusual patterns in ringworm rashes, like this "double-edged" pattern that is several inches wide. Long term use of these corticosteroid creams combination may lead to severe redness and burning with ringworm. Thus, owing to the above factors the market is expected to face a major restraint over the forecast period.

Segment Analysis

The global athlete's foot drugs market is segmented based on type, product type, drug class, distribution channel, and region.

Owing to its Better Effectiveness, the Anti Fungal Segment Accounted for Approximately 42.8% of the Athlete's Foot Drugs Market Share

The anti fungal segment is poised to dominate the athlete's foot drugs market as it remains a first-line and preferred medical treatment for athlete's foot drugs owing to its effectiveness, advancements in formulations, and better efficacy for treating athlete's foot disorder. The most commonly used drugs are clotrimazole, miconazole, tolnaftate or terbinafine, fluconazole, itraconazole.

Furthermore, the availability of over-the-counter (OTC) drugs in the forms of creams, gels, sprays makes antifungal class a preferred choice. Terbinafine (Lamisil AT), an antifungal, has been demonstrated to be particularly effective. Clotrimazole (Lotrimin AF) is another possibility. Moreover, new product approval will propel the market forward, for instance, in May 2022, Bayer's Consumer Health division announced the launch of the new and improved Canesten anti-fungal treatment solution in India. This medication provides relief from ringworm, jock itch, skin candidiasis, athlete's foot, erythrasma and fungal nail infection. Thus, owing to the above factors the segment is expected to dominate over the forecast period.

Geographical Penetration

North America Accounted for Approximately 39.5% of the Market Share in 2022, Owing to the Prevalence of Athlete's Foot and Increasing Research Activities

North America, particularly the U.S., dominates the global athlete's foot drugs market due to its presence of established market players, along with increasing R&D activities. Furthermore, the increasing number of clinical trials led to novel treatments for better patient outcomes.

The rising prevalence of fungal disease such as dermatophytosis due to which athlete's foot is caused in U.S. is expected to drive the region. For instance, according to Center for Disease Control and Prevention article of 2023, dermatophytosis (ringworm) has resulted with 690 hospitalization, and 4,981,444 in U.S. Thus, this increasing number of hospitalization can be restricted by providing appropriate drug for better health outcomes.

Morover, increasing number of R&D activities and clinical trial in this region will lead to advancements in treatment options. For instance, DermBiont, Inc., a clinical stage precision dermatology company is conducting a clinical trial to evaluate the safety and efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in subjects with tinea pedis based on Whole Genome Sequencing (WGS) and Quantitative Polymerase Chain Reaction (qPCR), and comparison between Quantitative Polymerase Chain Reaction (qPCR) and Potassium Hydroxide (KOH). The trial is randomized and observer-blind, with an Aqueous Gel as a control group. The gels will be used daily for roughly 6-8 days during the study. Thus, owing to the factor stated above, the market in this region is expected to grow over the forecast period.

Competitive Landscape

The major global players in the athlete's foot drugs market include: Novartis AG, Vibcare Pharma Pvt. Ltd., Bayer AG, Taro Pharmaceutical Industries Ltd, GLENMARK PHARMACEUTICALS LTD., Abigail Healthcare Pharmaceutical, Sebela Pharmaceuticals, ANI Pharmaceuticals, Inc. and Perrigo Company plc among others.

COVID-19 Impact Analysis

COVID-19 most likely raises the risk of fungal infections such as athlete's foot due to its effect on the immune system and the fact that COVID-19 therapies (such as steroids and other medicines) might decrease the body's defenses against fungus.

Research conducted by the Centers for Disease Control and Prevention discovered that patients brought to the hospital with covid-19 were more likely to die if they also had a fungal infection. Patients with covid-19 and a fungal infection died at a rate of 48.5% during the pandemic, compared to 12.3% in patients with only fungal infections.

Regardless of the precise fungal pathogens involved, dual covid-19 and fungal infections resulted in longer hospital admissions, greater rates of critical care treatment, more usage of invasive mechanical ventilation, and more mortality. Thus, Covid-19 has created a major impact on athlete's foot market.

By Type

• Toe Web Infection
• Moccasin-type Infection
• Vesicular-type Infection
• Ulcerative Infection

By Product Type

• Topical Creams and Ointments
• Sprays
• Lotions
• Oral Medications
• Others

By Drug Class

• Antifungal Agents
• Corticosteroid
• Antibiotics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On June 20, 2022, Kerasal announced the launch of a new Athlete's Foot product line that includes a unique formula with 5-in-1 advantages to not only treat and heal most athlete's foot but also improve skin appearance and support a healthy footcare routine. The new Athlete's Foot products, which include the Athlete's Foot Invisible Powder Spray and Athlete's Foot Silky Clear Gel, are the latest additions to the brand's foot care range.
• On November 1, 2022, Zydus received approval from the Subject Expert Committee (SEC) of the Central Drug Standard Control Organization (CDSCO) to manufacture and market the antifungal drug Naftifine HCL 2% Cream in the country for the treatment of superficial fungal infections of the skin (Tinea corporis and Tinea cruris).
• On December 22, 2022, Synokem Pharmaceutical has received approval from the Central Drug Standard Control Organization's (CDSCO) Subject Expert Committee (SEC) to manufacture and market the antifungal drug Naftifine HCL Cream 2% w/w for the treatment of superficial fungal infection of the skin.

DMI Opinion

The global athlete's foot drugs market appears to be on the rise, owing to factors such as a change toward an active lifestyle, the prevalence of infectious diseases and diabetes, and an aging population. Consumer preferences for natural remedies and the development of new treatment choices reflect the market's breakthrough period. The possibility of side effects and the challenges posed by the COVID-19 pandemic, on the other hand, should not be neglected. The market's outcome will be influenced by how well these difficulties are addressed, as well as how effectively the industry continues to develop and meet consumer needs.

Why Purchase the Report?

• To visualize the global athlete's foot drugs market segmentation based on type, product type, drug class, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of athlete's foot drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global athlete's foot drugs market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Product Type
• 3.3. Snippet by Drug Class
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Prevalence of Diabetic People
    • 4.1.1.2. The Rising Prevalence of Obesity
    • 4.1.1.3. The Growing Geriatric Population
  • 4.1.2. Restraints
    • 4.1.2.1. The Side Effects Associated with the Athlete's Foot Drugs
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Demand for Personalized Medicine
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Toe Web Infection*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Moccasin-type Infection
• 7.4. Vesicular-type Infection
• 7.5. Ulcerative Infection

8. By Product Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.1.2. Market Attractiveness Index, By Product Type
• 8.2. Topical Creams and Ointments*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Sprays
• 8.4. Lotions
• 8.5. Oral Medications
• 8.6. Others

9. By Drug Class

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.1.2. Market Attractiveness Index, By Drug Class
• 9.2. Antifungal Agents*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Corticosteroid
• 9.4. Antibiotics
• 9.5. Others

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Spain
    • 11.3.7.5. Italy
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Novartis AG*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Vibcare Pharma Pvt. Ltd.
• 13.3. Bayer AG
• 13.4. Taro Pharmaceutical Industries Ltd
• 13.5. GLENMARK PHARMACEUTICALS LTD.
• 13.6. Abigail Healthcare Pharmaceutical
• 13.7. Sebela Pharmaceuticals
• 13.8. ANI Pharmaceuticals, Inc.
• 13.9. Perrigo Company plc
• 13.10. Xiromed

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us